JP2009511905A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511905A5
JP2009511905A5 JP2008535546A JP2008535546A JP2009511905A5 JP 2009511905 A5 JP2009511905 A5 JP 2009511905A5 JP 2008535546 A JP2008535546 A JP 2008535546A JP 2008535546 A JP2008535546 A JP 2008535546A JP 2009511905 A5 JP2009511905 A5 JP 2009511905A5
Authority
JP
Japan
Prior art keywords
alzheimer
disease
cell
subject
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008535546A
Other languages
English (en)
Japanese (ja)
Other versions
JP4908514B2 (ja
JP2009511905A (ja
Filing date
Publication date
Priority claimed from US11/246,524 external-priority patent/US7595167B2/en
Priority claimed from PCT/US2005/036014 external-priority patent/WO2007043998A1/en
Priority claimed from PCT/US2006/022156 external-priority patent/WO2007044094A1/en
Application filed filed Critical
Priority claimed from PCT/US2006/037186 external-priority patent/WO2007047029A2/en
Publication of JP2009511905A publication Critical patent/JP2009511905A/ja
Publication of JP2009511905A5 publication Critical patent/JP2009511905A5/ja
Application granted granted Critical
Publication of JP4908514B2 publication Critical patent/JP4908514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008535546A 2005-10-11 2006-09-25 アルツハイマー病に特異的なerk1/erk2リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー(adsmb) Expired - Fee Related JP4908514B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/246,524 2005-10-11
US11/246,524 US7595167B2 (en) 2005-10-11 2005-10-11 Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
PCT/US2005/036014 WO2007043998A1 (en) 2005-10-11 2005-10-11 Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
USPCT/US2005/036014 2005-10-11
USPCT/US2006/022156 2006-06-07
PCT/US2006/022156 WO2007044094A1 (en) 2005-10-11 2006-06-07 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
PCT/US2006/037186 WO2007047029A2 (en) 2005-10-11 2006-09-25 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)

Publications (3)

Publication Number Publication Date
JP2009511905A JP2009511905A (ja) 2009-03-19
JP2009511905A5 true JP2009511905A5 (enExample) 2009-11-12
JP4908514B2 JP4908514B2 (ja) 2012-04-04

Family

ID=37067652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535546A Expired - Fee Related JP4908514B2 (ja) 2005-10-11 2006-09-25 アルツハイマー病に特異的なerk1/erk2リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー(adsmb)

Country Status (10)

Country Link
US (1) US20180024146A1 (enExample)
EP (5) EP2322934B1 (enExample)
JP (1) JP4908514B2 (enExample)
KR (2) KR20140002073A (enExample)
AT (1) ATE431558T1 (enExample)
CA (1) CA2625300C (enExample)
DE (1) DE602006006855D1 (enExample)
ES (5) ES2412268T3 (enExample)
TW (2) TW201413246A (enExample)
WO (1) WO2007044094A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305234T3 (es) 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
JP2009544753A (ja) * 2006-07-28 2009-12-17 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 細胞成長、シナプスリモデリング及び長期記憶の固定を刺激する方法
WO2008100449A2 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
WO2010014588A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
AU2009285766A1 (en) * 2008-08-27 2010-03-04 H. Lundbeck A/S System and methods for measuring biomarker profiles
US20110212474A1 (en) * 2009-10-02 2011-09-01 Blanchette Rockefeller Neurosciences Institute Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
JP6058395B2 (ja) * 2009-10-02 2017-01-11 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の診断のための繊維芽細胞成長パターン
EP2707693B1 (en) * 2011-05-12 2016-10-12 Florin V. Chirila Peripheral diagnostic methods for screening alzheimer's disease using beta amyloid and intercellular communication
JP6563193B2 (ja) 2011-11-13 2019-08-21 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Dcplaのエステル、およびそれを用いた処置の方法
KR101351978B1 (ko) * 2012-10-30 2014-01-16 주식회사 코씨드바이오팜 참치 안구 파쇄물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
JP6679489B2 (ja) * 2014-01-03 2020-04-15 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病についての有効な末梢診断法に対する凝集率の収束
KR102357045B1 (ko) 2017-03-31 2022-01-28 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 형태계측 시험
EP3972975A4 (en) * 2019-05-23 2023-11-15 Indiana University Research and Technology Corporation METHODS FOR OBJECTIVE MEMORY ASSESSMENT, EARLY DETECTION OF RISK FOR ALZHEIMER'S DISEASE, MATCHING INDIVIDUALS TO TREATMENTS, MONITORING RESPONSE TO TREATMENT, AND NEW METHODS OF USING DRUGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US20030108956A1 (en) * 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
ES2305234T3 (es) 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
KR100574017B1 (ko) 2003-08-11 2006-04-26 삼성전자주식회사 잉크젯 프린터의 잉크 카트리지
US7199386B2 (en) 2004-07-29 2007-04-03 General Electric Company System and method for detecting defects in a light-management film

Similar Documents

Publication Publication Date Title
JP2009511905A5 (enExample)
Hu et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay
Hwang et al. Impaired GAPDH‐induced mitophagy contributes to the pathology of Huntington's disease
Teunissen et al. Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid
AU2010291933B2 (en) Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
CN102762986B (zh) 阿尔茨海默病的诊断方法
DK1355949T3 (da) Antistoffer mod konformationelt abnorme former af tau-protein der forekommer i væv ved Alzheimers sygdom
WO2007062090A3 (en) Methods and compositions related to b cell assays
EP2322932A3 (en) Detection of tuberculosis and infection by mycobacterium tuberculosis using HBHA
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
JP2007508527A5 (enExample)
WO2001062968A3 (en) Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
JP5677297B2 (ja) 神経変性疾患の診断/予後判定の指標としてのグルタミニルシクラーゼ
US20150160240A1 (en) Host Biomarkers for Dengue Fever (DF) and Methods Thereof
EP2770066A3 (en) Compositions and methods for detecting mutations in JAK2 nucleic acid
WO2005019471A3 (en) Periostin-like factor: compositions and methods for making and using the same
US20090246816A1 (en) Methods and kits for selecting an analgesic regime
RU2008123385A (ru) Способы диагностики заболеваний печени и скрининга молекул для лечения этих заболеваний
WO2010092488A3 (en) Method for evaluating risk in multiple sclerosis
MX2013002820A (es) Estraficacion de pacientes con cancer para determinar la susceptibilidad al tratamiento con inhibidores de ptk2.
WO2005108619A3 (en) Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
Bao et al. Is It Appropriate to Adjust the Uric Acid Reference Interval?
RU2830412C1 (ru) Способ прогнозирования риска развития дыхательной недостаточности у больных с внебольничной пневмонией на фоне инфицирования SARS-CoV2
RU2006124937A (ru) Способ прогнозирования течения сахарного диабета 1 типа
Alavian et al. Commentary on “risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States”